Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Colorectal Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 131Cyclophosphamide 74fludarabine phosphate 51Whole-Body Irradiation 38Peripheral Blood Stem Cell Transplantation 36Mycophenolic Acid 36Tacrolimus 32Etoposide 28Busulfan 28Melphalan 24Lenalidomide 23Prednisone 22Filgrastim 22Cyclosporine 22Bortezomib 22Antilymphocyte Serum 21Vincristine 19Methotrexate 19obinutuzumab 17Bendamustine Hydrochloride 16fludarabine 15Doxorubicin 15Radiotherapy 14ibrutinib 13Dexamethasone 13Cytarabine 13Cord Blood Stem Cell Transplantation 13Carmustine 13pembrolizumab 12idelalisib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Follicular × Maraviroc × Clear all
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡